



Where **great minds**
and **smart money**
meet **under one roof**

Preliminary Programme

biotrinity 2011

12-14 April
Newbury Racecourse, UK

Organised by
obn

www.biotrinity.com

Sponsors of BioTrinity 2011*

Platinum Sponsors



Silver Sponsors



Bronze Sponsors




Investor



Media & PR Agent



Project Partners



BIOTRINITY 2011 PRELIMINARY PROGRAMME*

Tuesday, 12th April 2011

18.00	Pre-conference registration and Grand Opening Reception – sponsored by MEPC All registered delegates welcome to attend
-------	--

Wednesday, 13th April 2011

08.00	Registration and Exhibition open			
08.45	Welcome and Opening Remarks , Dr Jon Rees, CEO, OBN			
08.50	VIP address: Professor Colin Blakemore, University of Oxford			
09.00	Panel Discussion: <i>Is Corporate Venture Replacing Traditional Venture?</i> Chaired by Debbie Harland, SROne Roel Bulthuis, Merck Serono Ventures Gwen Melincoff, Shire Strategic Investment Group Martin Heidecker, Boehringer Ingelheim Venture Fund Johan Kördel, Senior Investment Director, Lundbeckfond Ventures			
09.45	Panel Discussion: <i>Successes During Crises: How did they make it happen?</i> Chaired by Olivier Litzka, Edmond de Rothschild Iain Buchanan, Novoxel Ernest Loumaye, Preglem David Solomon, Zealand Pharma Dirk Reyn, CEO, Movetis Tim Haines, Abingworth			
11.00	Panel Discussion: <i>The Public Markets and Life Sciences: Experiences from the Frontline</i> Chaired by Raquel Hughes An investor: Andy Crossley, Invesco Perpetual An issuer: John Aston, ex FD CAT An Adviser: Ron Openshow, Lucia Capital Julian Baines, CEO, EKF Diagnostics Holdings plc			
11.45	Panel Discussion: <i>Positioning your company for Merger & Acquisition</i> Chaired by Finton Walton, PharmaVentures Senior executives from big pharma and mid-cap biotech will explore their recent acquisitions and mergers			
12.00-13.30	Innovation poster presentations (Level 1)			
13.30-17.30	Company Showcase: Sponsored by Shire Pharmaceuticals			
	Adaptimmune Amakem NV Aptotope Astex BioVex CellMedica	Cellzome Critical Pharmaceuticals Cytex E-Therapeutics plc Immunocore	Oxford Biomedica PhotoBiotics ProCarta BioSystems Pro-Cure Therapeutics	Protaffin Biotechnologie PsiOxus Syntaxin Silence Therapeutics
17.30-19.00	Networking Reception (Sponsored by Shire)			
19.15	Gala Dinner (Tickets to be purchased in advance)			

08.30 – 17.00

One-to-One
Partnering
meetings

Partnering

The gold standard partnering system enables you to select companies and arrange one-to-one meetings. Accepted meetings are then scheduled in private rooms or booths in the Berkshire Stand on:
13th April 2011: 08.30 – 17.30 hrs **14th April 2011: 08.30 – 16.30 hrs**

Partnering system provided by **partneringONE™**

Thursday, 14th April 2011

08.00	Registration and Exhibition open			
08.50	Key Notes Talk Mike Ward, Global Editor, SCRIP Intelligence <i>UK Life Sciences Financing: Recovery or False Dawn</i>			
09.00	Panel Discussion: <i>Where Will Investors Invest in 2012?</i> Leading VCs all with funds to invest and the leading French corporate advisory firm will discuss where investors will invest in 2012. Investment firms participating will also highlight their recent key deals as well as describe their sweet spots for 2012. Nigel Pitchford, Partner, DFJ Esprit Sofia Ioannidou, Edmond de Rothschild Investment Partners Gunnar Weikert, Chairman, Inventages Russ Cummings, Imperial Innovations			
09.45	Pharma Panel Discussion: <i>Innovative Pharma Deal Making</i> Chaired by Tibor Papp, PharmaVentures Margaret Beer, MSD Shaun Grady, AstraZeneca Philip Oliver, Eli Lilly (invited) Christopher Berry, sanofi Aventis (invited)			
11.00–11.15	Key Notes: Richard Seabrook, The Wellcome Trust			
11.15–11.30	Key Notes: Jon Rees: OBN's Party Political Broadcast			
13.30–15.30	Company Showcase:			
	Alchemy Healthcare Bicycle Therapeutics BioOxyDyn Conformetrix Cyprotex	Future Injections Technologies Michelsen Diagnostics MorphoSys	Nanosight Nanotherics Orthox Oxford Expression Technologies	Plasticell Therapeutics Phylogica Sanifit

08.00 – 16.30

One-to-One
Partnering
meetings

Workshops

Wednesday, 13th April 2011

13.30–14.00	Workshop title to be confirmed James Cowper , hosted by Sue Staunton, Partner
14.00–15.00	Workshop title to be confirmed Invest in Skane , Sweden
15.30–16.30	Workshop title to be confirmed Almac Group Drug Development Services , hosted by Helen McKeever
16.30–17.00	<i>Technology Adoption in the NHS</i> Oxfordshire Biomedical Research Centre , hosted by Dr Jenny Taylor

Thursday, 14th April 2011

11.00–12.00	Workshop title to be confirmed Morrison & Foerster
12.00–12.30	Workshop – available
13.30–14.00	<i>Provisioning bioinformatics for the next decade - are we prepared?</i> Eagle Genomics hosted by William Spooner
14.00–14.30	<i>The best three UK Innovation Posters to present their findings</i>
14.30–15.30	<i>Diagnostic Cluster presentations</i>

About BioTrinity 2011

Biotrinity 2011 will be the largest gathering of the UK's Bioindustry attracting an expected 750 delegates and is Europe's fastest growing Biopartnering and Investment Conference. This annual conference attracts a multitude of investors, senior licensing executives from global pharma and the senior management of innovative R&D companies from the biotech as well as medtech sectors.

Using the gold standard partnering system for the life science industry delegates can request to meet companies across the sector and all agreed meetings are scheduled in **private rooms** and **booths**, a feature unique to BioTrinity.

BioTrinity 2011's exciting programme will bring you the most essential news and ideas from key players in pharma and the investment world. Hear from the leading minds in bio funding, offering insight into securing investment through the latest Corporate Venture Funds. Be inspired, as some of pharma's hottest dealmakers come together to offer you a fresh perspective on successful strategies during tough economic times.

Hand-picked company presentations showcase the UK's best biotech and medtech companies and high level interactive workshops will give you up to date industry advice and trends. There are plenty of opportunities for informal networking at the networking hubs within the industry exhibition and the vibrant social events programme.

What delegates say about BioTrinity

"I attended BioTrinity 2010, and I am very pleased to return this year to present at BioTrinity 2011 having raised investment from Morningside following our meeting at the conference. BioTrinity is the number one investment conference." Michael McArthur, CSO, **Procarta Biosystems**

"BioTrinity has come of age as a major partnering event. There also appear to be more investors in attendance than at competing events" Simon Haworth, **IPSO Ventures**

"I presented at BioTrinity 2009, and was delighted to return this year to BioTrinity 2010 having raised a significant investment from TRI Inc following our initial one-to-one meeting at the conference. BioTrinity is the number one conference for fundraising" Eddy Littler, CEO, **Domainex**

BioTrinity 2011 highlights

- 75+ investor firms expected to attend
- 75% of world's top global pharma companies
- 2 full days of one-to-one partnering



Who will you meet at BioTrinity?

- UK's best biotech and medtech companies
- More investors than any other UK conference
- Largest number of global pharma licensing executives yet
- The largest gathering of the UK bioindustry

2010 Statistics:

- 625+ delegates from 20 countries
- 1300 partnering meetings (up 70%),
- 62 investment firms from 10 countries
- Two-thirds of top 20 global pharma



Partnering

Pre-arranged one-to-one meetings in private booths with 750 executives



Presentations

Up to 50 corporate presentations from a hand-picked list of the best UK life science companies



Workshops

Interactive workshops on the latest industry trends and advice



Panels

Global pharma and investors discuss financing, licensing and acquisition strategies



Exhibition

High traffic exhibition incorporating informal networking hubs



Networking

Grand Opening Reception, Investor-only tasting dinner, Gala Dinner

Registration Fees

Standard Registration fee (after 14 February) **£699 + VAT**

On-site registration fee (after 12 April) **£800 + VAT**

Register on-line at www.biotrinity.com

Exhibiting and Sponsorship

Sponsorship and Exhibition opportunities are available for companies seeking maximum exposure. We can develop a package of benefits tailored to meet your company needs and budget. Contact Hilary Boardman to discuss your ideas.

Companies confirmed at 3 February 2011

INVESTORS					
Abingworth LLP	Shire Strategic Investment Group	Charles Russell LLP	Innovacell Biotechnologie AG (Austria)	Centre	Riverbank IT Management Ltd
Advent Venture Partners	Singer Capital Markets	Chroma Therapeutics	Interea International	Oxford Brookes University	RSSL Pharma
Aelios Finance (France)	SPARK Ventures	Cinetique Translations	International Bioscience Managers	Oxford Expression Technologies	Rules Based Medicine, Inc. (US)
Aescap Venture (Netherlands)	SR One	Citigate Dewe Rogersen	International Labmate (Media)	Oxford Nutrascience Ltd	Safeguard Biosystems Holdings Ltd
Albion Ventures	Syngergis Technologies	Clinica (media)	Intertek Pharmaceutical Services	Oxford Science Park	SANIFIT Laboratoris (Spain)
Amadeus Capital Partners	Takeda Ventures, Inc. (US)	Colworth Science Park	Invest in Skane (Sweden)	Patheon UK Limited	nofi Aventis
Boehringer Ingelheim Venture Fund (Germany)	Technikos LLP	The Communications Strategy Group Inc. (US)	In Vivo (media)	PGXIS	Scancell Holdings plc
DFJ Esprit LLP	Versant EuroVentures (Switzerland)	Conformetrix	IPT Pharma	PharmaVentures	Scientific Laboratory Supplies
DSM Venturing (Netherlands)		Convergence Pharma	IPT Magazine (Press)	PharmaWire (media)	S-cubed
ECI Partners	Abgent Europe	Critical Pharmaceuticals	IQ Capital Partners LLP	PhotoBiotics	Shire plc
Edison Investment Research	Adaptimmune	C-TRIC	Isis Innovation	Phylogica	Shire-Movetis NV (Belgium)
Edmond de Rothchild Investment Partners (France)	Alchemy Healthcare	Cyprotex Discovery plc	JA Kemp & Co	Physiomics plc	Siegfried
Entrepreneurs Fund	Almac	Cytox	James Cowper	Pipeline Biotech (Denmark)	Silence Therapeutics
Forbion Capital Partners (NL)	Amakem NV (Belgium)	Defined Health (Switzerland)	J&J Development Corp. (US)	PIR Interims	Simbec Research Ltd
Genetrix SL (Spain)	A. Menarini IFR (Italy)	Dehns	Kelly Scientific Resources	Piramal Healthcare	SRA Global Clinical Development
H20 Venture Partners	Apitope	Drug Discovery Today (Media)	KPMG	Pivotal Scientific	SRCL
International Bioscience Managers	Aquapharma Discovery	Eagle Genomics	KWS Biotest	Plasticell Therapeutics	SRG
Inventages Venture Capital	Astex	EBD Group	LacertaBio Inc. (US)	Plethora Solutions	Stratagem IPM Ltd
Invesco Perpetual	Aston University	EFK Diagnostics (Germany)	Lab Support	Ploughshare Innovations	Syntaxin Ltd
IPSO Ventures	AstraZeneca	Eli Lilly	Liverpool Science Park	Polytherics	Syntagon (Sweden)
IQ Capital Partners LLP	AvantiCell Science	Elsevier (Press)	Manches LLP	PregLem (Switzerland)	Talentmark
J&J Development Corp. (US)	BASi	EpiStem plc	McEwen Labs	ProCarta Biosystems	Team Consulting
KBC Peel Hunt	Baxter Healthcare	Essen Bioscience	Melbourn Scientific	Pro-Cure Therapeutics Ltd	Teva
Lucia Capital	Bicycle Therapeutics	E-Therapeutics plc	MEPC	Prosidion (part of Astellas)	The Communications Strategy Group Inc. (US)
Lunbeckfond Ventures	BigBear Communications	Euprotec	MSD	Protaffin Biotechnologie (Austria)	The Electrospinning Company
Matrix Group Investment Banking Division	BioDundee	Fasken Martineau LLP	Michelson Diagnostics	Providion	TMRI
Merck Serono Ventures (Switzerland)	BioEdge	FOCUS Insurance	MorphoSys AG	QED Clinical Services	Tissue Solutions Ltd
Midven	BioOxyDyn	Forresters	Morrison & Foerster (Germany)	Quality Assistance (Belgium)	Total Scientific Ltd
Morningside (China / US)	BioPark/BABS Biomarker Services	Future Injection Technologies	Myotec Therapeutics	Quay Pharmaceuticals	TranScrip Partners LLP
MP Healthcare Venture Management, Inc. (US)	Biopharma Process Systems	Fry Heath Spence	NanoSight	Quest Diagnostics Clinical Trials	UMIC
MVM Life Science Partners LLP	Biotech Personnel	Gen-probe Life Sciences	Nanotherics	QuickSTAT	University of Missouri (US)
New Hill Management	BiotechSubsidy (Belgium)	Gen-probe Life Sciencesgeorge james	Novoxel (France)	Randex Pharma Services	University of Oxford
Novo A/S (Denmark)	Biotec Services International	GSK (CEEDD)	O2H	Raumedic	University of Southampton
Numis Securities	BioVex	Harwell Science Park	OCT Consulting (Russian Fed.)	Reading Scientific Services	Vantia Therapeutics
Oxford Capital Partners	Boult Wade Tennant	Health Protection Agency	OctoPlus (Netherlands)	Red Moon Executive Search	Vectura Group plc
Peel Hunt	Bridgehead International	High Force Research Ltd	ORSETEC	Reed Scientific	Veeda
SEP	CDSS	HMA Digital Marketing	Orthox	Regional Economic Development Inc. (US)	VWR International
	Cell Medica	Hypha Discovery	Osborne Clarke	Regulatory Resources Group Ltd	Wellcome Trust
	Cellzome	Immunocore	Oval Medical Technologies Ltd	Remtec Search and Selection	Xention
	Cels NEPAF	INC Research	Oxford Biomedica		Zealand Pharma (Denmark)
		Innova Biosciences Ltd	Oxford Biomedical Research		